ALKBH5 and renal cell carcinoma: Strick, von Hagen [189] identified aberrant expression of FTO and ALKBH5 in RCC by qRT-PCR and tissue microarray techniques, and found that reduced mRNA levels of ALKBH5 and FTO were associated with lower survival rates in RCC patients.